Nadege Pelletier - Jan 2, 2024 Form 4 Insider Report for Barinthus Biotherapeutics plc. (BRNS)

Role
Chief Scientific Officer
Signature
/s/ William Enright, Attorney-in-Fact
Stock symbol
BRNS
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 08:56 AM
Previous filing
Feb 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRNS Share Option (Right to Buy) Award $0 +105K $0.00 105K Jan 2, 2024 Ordinary Shares 105K $3.70 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.